Top-Rated StocksTop-RatedNASDAQ:AXNX Axonics (AXNX) Stock Forecast, Price & News $55.18 -0.22 (-0.40%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$54.76▼$59.3750-Day Range$50.60▼$62.5152-Week Range$47.59▼$77.20Volume463,622 shsAverage Volume659,641 shsMarket Capitalization$2.78 billionP/E RatioN/ADividend YieldN/APrice Target$76.36 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Axonics MarketRank™ ForecastAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside38.4% Upside$76.36 Price TargetShort InterestBearish6.12% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.86Based on 4 Articles This WeekInsider TradingSelling Shares$1.01 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.36) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector444th out of 964 stocksSurgical & Medical Instruments Industry53rd out of 98 stocks 3.5 Analyst's Opinion Consensus RatingAxonics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $76.36, Axonics has a forecasted upside of 38.4% from its current price of $55.18.Amount of Analyst CoverageAxonics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.12% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Axonics has recently increased by 7.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxonics does not currently pay a dividend.Dividend GrowthAxonics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Incontinence medication", "Implants and prostheses", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Axonics is -1.38. Previous Next 2.7 News and Social Media Coverage News SentimentAxonics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Axonics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for AXNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axonics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,013,714.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of Axonics is held by insiders.Percentage Held by Institutions99.00% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axonics are expected to grow in the coming year, from ($0.36) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics is -82.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics is -82.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axonics (NASDAQ:AXNX) StockAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Read More AXNX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXNX Stock News HeadlinesSeptember 22, 2023 | finance.yahoo.comUnveiling Axonics (AXNX)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 21, 2023 | americanbankingnews.comAxonics, Inc. (NASDAQ:AXNX) Sees Significant Increase in Short InterestSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 17, 2023 | americanbankingnews.comAxonics, Inc. (NASDAQ:AXNX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 11, 2023 | finance.yahoo.comAxonics (AXNX): A Significantly Undervalued Gem in the Medical Technology Sector?September 7, 2023 | seekingalpha.comAxonics: Growing Duopolist With Superior Product And No DebtAugust 25, 2023 | finance.yahoo.comAxonics to Participate in September Investor ConferencesAugust 21, 2023 | finance.yahoo.comAxonics Announces CFO Retirement and Appoints SuccessorSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJuly 31, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Axonics Modulation Technologies (AXNX) and SAGE Therapeutics (SAGE)July 29, 2023 | seekingalpha.comAxonics: Rapid Growth But Waiting For ProfitabilityJuly 28, 2023 | markets.businessinsider.comAnalyst Ratings for AxonicsJuly 28, 2023 | finance.yahoo.comWhy Shares of Axonics Rose FridayJuly 28, 2023 | washingtonpost.comAxonics: Q2 Earnings SnapshotJuly 24, 2023 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Axonics Modulation Technologies (AXNX)July 18, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Buy Rating for Axonics Modulation Technologies (AXNX)July 16, 2023 | markets.businessinsider.comTruist Financial Remains a Buy on Axonics Modulation Technologies (AXNX)July 13, 2023 | markets.businessinsider.comAxonics Positioned For Rapid Penetration In Underserved Market, Analyst Initiates With Bullish ToneJuly 13, 2023 | markets.businessinsider.comKeyBanc Initiates a Buy Rating on Axonics Modulation Technologies (AXNX)July 12, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for AxonicsJuly 10, 2023 | reuters.comUS appeals court revives Axonics challenges to Medtronic device patentsJune 29, 2023 | finance.yahoo.comAxonics to Report Second Quarter 2023 Financial Results on July 27May 31, 2023 | markets.businessinsider.comJefferies Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)May 31, 2023 | finance.yahoo.comEven though Axonics (NASDAQ:AXNX) has lost US$173m market cap in last 7 days, shareholders are still up 28% over 3 yearsMay 23, 2023 | markets.businessinsider.comWhere Axonics Stands With AnalystsMay 16, 2023 | finance.yahoo.comWhat Makes Axonics (AXNX) Unique?May 12, 2023 | seekingalpha.comAxonics: Attractive Strong Growth ProfileSee More Headlines Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXNX Company Calendar Last Earnings7/27/2023Today9/26/2023Next Earnings (Estimated)10/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXNX CUSIPN/A CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees610Year FoundedN/APrice Target and Rating Average Stock Price Forecast$76.36 High Stock Price Forecast$90.00 Low Stock Price Forecast$70.00 Forecasted Upside/Downside+38.3%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,700,000.00 Net Margins-10.06% Pretax Margin-10.73% Return on Equity-5.60% Return on Assets-4.94% Debt Debt-to-Equity RatioN/A Current Ratio14.19 Quick Ratio12.01 Sales & Book Value Annual Sales$273.70 million Price / Sales10.18 Cash FlowN/A Price / Cash FlowN/A Book Value$11.51 per share Price / Book4.80Miscellaneous Outstanding Shares50,460,000Free Float49,527,000Market Cap$2.79 billion OptionableNot Optionable Beta0.43 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Raymond W. Cohen (Age 64)CEO & Director Comp: $1.71MMr. Danny L. Dearen (Age 60)Pres & CFO Comp: $799.08kMr. Rinda K. Sama (Age 44)Chief Operating Officer Comp: $902.83kDr. John Woock Ph.D. (Age 40)Exec. VP, Chief Marketing & Strategy Officer Comp: $902.83kMr. Alfred J. Ford Jr. (Age 52)Chief Commercial Officer Comp: $902.96kMs. Kari KeeseVP of Fin. & AccountingMr. Guangqiang Jiang Ph.D. (Age 49)Chief Technology Officer Mr. Neil BhalodkarVP of Investor RelationsMr. Aaron PettitGen. Counsel & Chief Compliance OfficerMr. Michael V. Williamson Esq. (Age 51)J.D., Sr. VP, Gen. & IP Counsel More ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUIiRhythm TechnologiesNASDAQ:IRTCIntegra LifeSciencesNASDAQ:IARTGlaukosNYSE:GKOSInari MedicalNASDAQ:NARIView All CompetitorsInsiders & InstitutionsBarclays PLCSold 6,091 shares on 9/21/2023Ownership: 0.037%Virginia Retirement Systems ET ALBought 24,300 shares on 8/22/2023Ownership: 0.048%Comerica BankBought 10,001 shares on 8/22/2023Ownership: 0.020%California State Teachers Retirement SystemBought 7,240 shares on 8/21/2023Ownership: 0.119%Osaic Holdings Inc.Bought 1,642 shares on 8/21/2023Ownership: 0.022%View All Insider TransactionsView All Institutional Transactions AXNX Stock - Frequently Asked Questions Should I buy or sell Axonics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXNX shares. View AXNX analyst ratings or view top-rated stocks. What is Axonics' stock price forecast for 2023? 11 analysts have issued 1 year target prices for Axonics' shares. Their AXNX share price forecasts range from $70.00 to $90.00. On average, they predict the company's stock price to reach $76.36 in the next twelve months. This suggests a possible upside of 38.3% from the stock's current price. View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts. How have AXNX shares performed in 2023? Axonics' stock was trading at $62.53 at the beginning of 2023. Since then, AXNX shares have decreased by 11.7% and is now trading at $55.20. View the best growth stocks for 2023 here. Are investors shorting Axonics? Axonics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 3,090,000 shares, an increase of 7.7% from the August 15th total of 2,870,000 shares. Based on an average daily volume of 697,500 shares, the days-to-cover ratio is currently 4.4 days. View Axonics' Short Interest. When is Axonics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023. View our AXNX earnings forecast. How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) released its quarterly earnings data on Thursday, July, 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.03. The business had revenue of $92.90 million for the quarter, compared to analysts' expectations of $86.45 million. Axonics had a negative trailing twelve-month return on equity of 5.60% and a negative net margin of 10.06%. The company's revenue was up 34.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.47) earnings per share. What ETFs hold Axonics' stock? ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Nuveen Small Cap Select ETF (NSCS), Principal Healthcare Innovators ETF (BTEC) and Goldman Sachs Future Health Care Equity ETF (GDOC).iShares U.S. Medical Devices ETF (IHI). What guidance has Axonics issued on next quarter's earnings? Axonics issued an update on its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $358.00 million-$358.00 million, compared to the consensus revenue estimate of $358.73 million. What is Raymond W. Cohen's approval rating as Axonics' CEO? 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT). When did Axonics IPO? (AXNX) raised $100 million in an IPO on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. What is Axonics' stock symbol? Axonics trades on the NASDAQ under the ticker symbol "AXNX." Who are Axonics' major shareholders? Axonics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.46%), Bellevue Group AG (4.41%), Champlain Investment Partners LLC (3.45%), Credit Suisse AG (2.67%), State Street Corp (2.39%) and Geode Capital Management LLC (2.00%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara. View institutional ownership trends. How do I buy shares of Axonics? Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axonics' stock price today? One share of AXNX stock can currently be purchased for approximately $55.20. How much money does Axonics make? Axonics (NASDAQ:AXNX) has a market capitalization of $2.79 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. How many employees does Axonics have? The company employs 610 workers across the globe. How can I contact Axonics? Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321. This page (NASDAQ:AXNX) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.